|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 819.36 USD | +0.90% |
|
+6.43% | +6.13% |
| 06-13 | Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial | RE |
| 06-13 | S&P 500 Suffers Weekly Drop as Israel, Iran Launch Attacks | MT |
| Capitalization | 736B 636B 597B 541B 999B 63,332B 1,130B 6,979B 2,715B 28,993B 2,761B 2,701B 105,912B | P/E ratio 2025 * |
38.6x | P/E ratio 2026 * | 29.2x |
|---|---|---|---|---|---|
| Enterprise value | 760B 658B 617B 559B 1,033B 65,466B 1,168B 7,214B 2,807B 29,969B 2,854B 2,792B 109,480B | EV / Sales 2025 * |
12.8x | EV / Sales 2026 * | 10.5x |
| Free-Float |
99.81% | Yield 2025 * |
0.73% | Yield 2026 * | 0.82% |
More valuation ratios
* Estimated data
More news
Last Transcript: Eli Lilly and Company
More recommendations
More press releases
| 1 day | +0.90% | ||
| 1 week | +6.43% | ||
| Current month | +11.07% | ||
| 1 month | +14.51% | ||
| 3 months | +0.72% | ||
| 6 months | +3.83% | ||
| Current year | +6.13% |
| 1 week | 767.59 |  | 825 |
| 1 month | 709 | | 825 |
| Current year | 677.09 | | 935.62 |
| 1 year | 677.09 | | 972.53 |
| 3 years | 283.11 | | 972.53 |
| 5 years | 129.21 | | 972.53 |
| 10 years | 64.18 | | 972.53 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 57 | 2016-12-31 |
Ruth Gimeno
PSD | President | - | - |
Lucas Montarce
DFI | Director of Finance/CFO | 48 | 2024-09-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Fyrwald
BRD | Director/Board Member | 64 | 2004-12-31 |
Ralph Alvarez
BRD | Director/Board Member | 69 | 2009-03-31 |
| Director/Board Member | 53 | 2011-12-11 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 6.49% | 21 M€ | +0.03% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.90% | +6.43% | -6.73% | +181.77% | 736B | ||
| +0.28% | +1.34% | +7.94% | -6.59% | 378B | ||
| -0.58% | +5.27% | -47.91% | +36.67% | 355B | ||
| -0.70% | +0.66% | +13.34% | +38.85% | 338B | ||
| -1.06% | +0.56% | +8.93% | -11.79% | 266B | ||
| -0.93% | +0.08% | +2.26% | +20.37% | 235B | ||
| -0.40% | +1.89% | -12.18% | +12.68% | 232B | ||
| -0.13% | +3.47% | -36.89% | -3.30% | 205B | ||
| -0.70% | +1.68% | -1.14% | +25.25% | 159B | ||
| -1.21% | +5.10% | -10.86% | -48.79% | 140B | ||
| Average | -0.45% | +2.94% | -8.32% | +24.51% | 304.24B | |
| Weighted average by Cap. | -0.19% | +3.35% | -7.77% | +52.08% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 59.57B 51.53B 48.35B 43.82B 80.9B 5,129B 91.5B 565B 220B 2,348B 224B 219B 8,577B | 71.42B 61.78B 57.97B 52.54B 96.99B 6,149B 110B 678B 264B 2,815B 268B 262B 10,283B |
| Net income | 19.1B 16.53B 15.51B 14.05B 25.95B 1,645B 29.35B 181B 70.53B 753B 71.71B 70.16B 2,751B | 25.19B 21.79B 20.45B 18.53B 34.21B 2,169B 38.7B 239B 93B 993B 94.56B 92.52B 3,627B |
| Net Debt | 24.79B 21.44B 20.12B 18.23B 33.66B 2,134B 38.07B 235B 91.5B 977B 93.03B 91.03B 3,569B | 12.19B 10.54B 9.89B 8.96B 16.55B 1,049B 18.72B 116B 44.99B 480B 45.74B 44.75B 1,755B |
More financial data
* Estimated data
Employees
47,000
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-13 | 819.36 $ | +0.90% | 2,754,603 |
| 25-06-12 | 812.03 $ | +0.42% | 2,271,087 |
| 25-06-11 | 808.61 $ | +0.18% | 3,125,380 |
| 25-06-10 | 807.19 $ | +4.33% | 4,744,424 |
| 25-06-09 | 773.71 $ | +0.50% | 2,262,158 |
Delayed Quote Nyse, June 13, 2025 at 04:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
819.36USD
Average target price
951.98USD
Spread / Average Target
+16.19%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition